ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 14, 2025. This episode summarizes 5 key cardiology studies on topics like ischemic cardiomyopathy and ventricular tachycardia. Key takeaway: Sacubitril-Valsartan for Chemo Cardiotoxicity.
Article Links:
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine)
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation)
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal)
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal)
Article 5: Exploring postmortem practices for cardiac device interrogation in the UK. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/
Featured Articles
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159885
Summary: This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41230611
Summary: The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879135
Summary: The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40737218
Summary: This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.
Article 5: Exploring postmortem practices for cardiac device interrogation in the UK.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224486
Summary: This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.
Transcript
Today’s date is November 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Deferring Arterial Catheterization in Critically Ill Patients with Shock. This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.
Article number two. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.
Article number three. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.
Article number four. Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.
Article number five. Exploring postmortem practices for cardiac device interrogation in the UK. This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.
Thank you for listening. Don’t forget to subscribe.
Keywords
ischemic cardiomyopathy, ventricular tachycardia, postmortem, anthracycline cardiotoxicity, arterial catheterization, chemotherapy, heart failure with reduced ejection fraction, sudden death, intensive care unit, shock, cardiac device interrogation, noninvasive blood pressure monitoring, sudden cardiac death, cardiac troponin I, wearable cardioverter-defibrillator, heart failure hospitalization, cardiac implantable electronic device, non-ischemic cardiomyopathy, kidney function, prognosis, critically ill patients, sacubitril-valsartan, coroners, cardioprotection, estimated glomerular filtration rate.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25 first appeared on Cardiology Today.
Article Links:
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock. (The New England journal of medicine)
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. (Circulation)
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. (European heart journal)
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. (European heart journal)
Article 5: Exploring postmortem practices for cardiac device interrogation in the UK. (Heart (British Cardiac Society))
Full episode page: https://podcast.explainheart.com/podcast/sacubitril-valsartan-for-chemo-cardiotoxicity-11-14-25/
Featured Articles
Article 1: Deferring Arterial Catheterization in Critically Ill Patients with Shock.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41159885
Summary: This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.
Article 2: Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41230611
Summary: The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.
Article 3: Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879135
Summary: The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.
Article 4: Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40737218
Summary: This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.
Article 5: Exploring postmortem practices for cardiac device interrogation in the UK.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41224486
Summary: This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.
Transcript
Today’s date is November 14, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Deferring Arterial Catheterization in Critically Ill Patients with Shock. This multicenter, open-label noninferiority trial investigated whether noninvasive blood pressure monitoring via an automated brachial cuff is an effective alternative to early arterial catheterization for critically ill patients in shock. Patients admitted to an intensive care unit with shock were randomized to receive either an arterial catheter within four hours or to be monitored noninvasively. The study’s objective was to determine if deferring invasive monitoring is noninferior to immediate arterial catheterization. This research establishes a rigorous comparison to potentially guide future management strategies for blood pressure monitoring in this vulnerable population.
Article number two. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. The SARAH Trial, a randomized double-blind placebo-controlled study, investigated the efficacy of sacubitril-valsartan in preventing anthracycline-induced cardiotoxicity. This trial enrolled 114 patients who developed elevated cardiac troponin I concentrations during anthracycline chemotherapy. The primary objective was to determine if this angiotensin receptor-neprilysin inhibitor could reduce cardiotoxicity in this high-risk population. This research aimed to translate experimental evidence of cardioprotective properties into a clinical benefit for patients undergoing critical cancer treatment.
Article number three. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. The German nationwide S. C. D. minus PROTECT study aimed to evaluate the risk of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation in patients with newly diagnosed non-ischemic cardiomyopathy or ischemic cardiomyopathy. This study utilized wearable cardioverter-defibrillators in all eligible patients across Germany to assess these events during the critical early phase of guideline-recommended medical therapy initiation and up-titration. The research directly addressed the increased sudden cardiac death risk in this vulnerable population by providing real-world data on event rates observed with temporary defibrillator use.
Article number four. Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. This study examined kidney function trajectories before and after a heart failure-related event, defined as heart failure hospitalization or heart failure death, in patients with heart failure with reduced ejection fraction. Researchers utilized individual patient data from the EPHESUS and EMPHASIS-H. F. clinical trials, alongside the real-world BARCELONA cohort, to analyze longitudinal changes in estimated glomerular filtration rate. The primary objective was to clarify the associations between these kidney function changes and subsequent heart failure-related events. This comprehensive approach establishes a framework for better understanding the prognostic impact of kidney function dynamics in this patient group.
Article number five. Exploring postmortem practices for cardiac device interrogation in the UK. This study explored postmortem practices for cardiac device interrogation in the United Kingdom, addressing the difficulty in ascertaining the cause of sudden death in patients with cardiac implantable electronic devices. The research aimed to determine the frequency of postmortem device interrogation and how the derived information is recorded and utilized by clinical teams and coroners. By evaluating the current capacity and usage of this diagnostic tool, the study establishes a baseline understanding of a critical process. This investigation could inform future guidelines to optimize the use of cardiac implantable electronic devices in clarifying causes of death.
Thank you for listening. Don’t forget to subscribe.
Keywords
ischemic cardiomyopathy, ventricular tachycardia, postmortem, anthracycline cardiotoxicity, arterial catheterization, chemotherapy, heart failure with reduced ejection fraction, sudden death, intensive care unit, shock, cardiac device interrogation, noninvasive blood pressure monitoring, sudden cardiac death, cardiac troponin I, wearable cardioverter-defibrillator, heart failure hospitalization, cardiac implantable electronic device, non-ischemic cardiomyopathy, kidney function, prognosis, critically ill patients, sacubitril-valsartan, coroners, cardioprotection, estimated glomerular filtration rate.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Sacubitril-Valsartan for Chemo Cardiotoxicity 11/14/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust